Jure Fettich, treasurer
D.03 Membership in foreign/international boards/committees
PURPOSE Precise tumor localization is crucial for treatment planing as well as for treatment evaluation and early detection of recurrence after primary therapy. In this abstract we evaluate first small group of patients that were scaned in our institution for brain gliomas. We want to confirm from our expirience that 18F-fluorethyltyrosine PET (18F-FET PET) can be used for treatment related changes, for detection residual tumour and for gross tumour volume (GTV) delineation in brain gliomas. MATERIAL AND METHODS We evaluated data of 3 patients with high-grade gliomas after multimodal treatment. Two patients have had recidivant high-grade glioma (anaplastic astrocytoma and anaplastic oligoastrocytoma); one patient before another radiotheraphy and one during systemic chemotherapy. Third patient with glioblastoma multiforme after surgery recived incomplete radiotherapy. We performed dynamic 18F-FET PET studies (0–60 min after injection of 200 MBq of 18F-FET) and results combined with MRI. RESULTS One patient with glioblastoma multiforme treated with surgery and incomplete radiochemotherapy had no evidence of disease detectable by 18F-FET PET . One patient that had 18F-FET PET scan done during systemic chemotherapy had partial response on MRI exam by the RANO criteria but there was still uptake of radiolebeled amino acids detected in area of interest. One patient with recurrent astrocytoma grade III had more extensive disease detected by 18F-FET PET than on MRI exam. CONCLUSIONS The best-studied amino acid tracer is 11C-methionine. Because of the short half-life of 11C (20 min), 18F-labeled aromatic amino acid analogs have been developed for tumor imaging. Tumor uptake of 18F-fluorethyltyrosine has been reported to be similar to that of 11C-methionine. Diagnostic accuracy and treatment related changes of brain gliomas can benefit from coregistration of 18F-FET PET results and MRI, combining the high-resolution morphologic images with the biologic information.
F.17 Transfer of existing technologies, know-how, methods and procedures into practice
Petra Kolenc Peitl, Radiopharmacy C member
D.03 Membership in foreign/international boards/committees